Efficacy and safety of liposomal amphotericin B for the treatment of mucosal leishmaniasis from the new world: A retrospective study
Am. j. trop. med. hyg
; 93(6): 1214-1218, Dec. 2015.
Article
in English
| Sec. Est. Saúde SP, SESSP-IIERPROD, Sec. Est. Saúde SP
| ID: biblio-1017266
Responsible library:
BR31.1
Localization: BR31.1; 2015_P-048
ABSTRACT
The standard treatment of mucosal leishmaniasis (ML) is pentavalent antimonials, agents with serious adverse effects. Alternative agents include amphotericin B deoxycholate and liposomal amphotericin B. We performed a retrospective study including 29 patients treated with liposomal amphotericin B, most of whom had comorbidities, history of previous treatment of ML, and contraindications to the use of antimonial pentavalent or amphotericin B deoxycholate. We observed a cure rate of 93.1%. Kidney failure was the most important side effect, reported in five patients (17.2%). This study showed a good efficacy and safety profile of liposomal amphotericin B in patients with ML and contraindications to the use of other agents
Full text:
Available
Collection:
National databases
/
Brazil
Database:
Sec. Est. Saúde SP
/
SESSP-IIERPROD
Main subject:
Amphotericin B
Type of study:
Observational study
Limits:
Humans
Language:
English
Journal:
Am. j. trop. med. hyg
Year:
2015
Document type:
Article
Institution/Affiliation country:
Secretaria de Estado da Saúde. São Paulo/BR